0
0 (0%)
Bionomics Limited [BNOEF]
Source:
Company Overview
Bionomics Limited is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Ion channels serve as important mediators of physiological function in the CNS and the modulation of ion channels influences neurotransmission that leads to downstream signaling in the brain.
| Country | United States |
| Headquarters | eastwood |
| Phone Number | 61 8 8150 7400 |
| Industry | manufacturing |
| CEO | Spyros Papapetropoulos |
| Website | www.bionomics.com.au |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0.7 |
| Operating Profit | $-3.7 |
| Net Income | $-1.9 |
| Net Cash | $-8.3 |
Profit Ratios
| Gross Margin | $0.7 |
| Operating Margin | -558.8 |
| Profit as % of Revenues | -34.1% |
| Profit as % of Assets | -8.5% |
| Profit as % of Stockholder Equity | -14.1% |
Management Effectiveness
| Return on Equity | -14.1% |
| Return on Assets | -10.7% |
| Turnover Ratio | 2.9% |
| EBITA | $-3.7 |
Balance Sheet and Cash Flow Measures
| Total Assets | $18.2 |
| Total Liabilities | $4.4 |
| Operating Cash Flow | $-7.8 |
| Investing Cash Flow | |
| Financing Cash Flow | $-0.3 |
